# A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers

> **NCT02583542** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Queen Mary University of London** · enrollment: 118 (estimated)

## Conditions studied

- Triple-Negative Breast Cancer
- Squamous Cell Lung Cancer
- Non-squamous Cell Lung Cancer With KRAS Mutations
- Non-squamous Cell Lung Cancer With Wild-type KRAS

## Interventions

- **DRUG:** AZD2014
- **DRUG:** AZD6244

## Key facts

- **NCT ID:** NCT02583542
- **Lead sponsor:** Queen Mary University of London
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-06
- **Primary completion:** 2020-03
- **Final completion:** 2020-03
- **Target enrollment:** 118 (ESTIMATED)
- **Last updated:** 2020-02-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02583542

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02583542, "A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT02583542. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*